LGALS1 and acute myeloid leukemia: The administration of LGALS1 inhibitors to primary AML cells derived from patients, cell lines, and AML animal transplant models could help to eliminate QSCs (a cell population involved in resistance to AML chemotherapy and poor prognosis) and enhance the efficacy of chemotherapy (74).